Recurrence of light chain deposit disease after renal allograft transplantation: Potential role of rituximab?

Transplant International

Volumn 20, Issue 4, 2007, Pages 381-385

  Kuypers, Dirk R J ^a   Lerut, Evelyne ^a   Claes, Kathleen ^a   Evenepoel, Pieter ^a   Vanrenterghem, Yves ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Anti CD20 monoclonal antibody; Kidney transplantation; Light chain deposit disease; Mabthera; Recurrence; Renal allograft; Rituximab

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALLOTRANSPLANTATION; ARTICLE; BLOOD CELL COUNT; BONE MARROW EXAMINATION; CASE REPORT; CHRONIC KIDNEY FAILURE; DISEASE COURSE; ELECTRON MICROSCOPY; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HUMAN; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; LIGHT CHAIN; LIGHT CHAIN DEPOSIT DISEASE; LIVING DONOR; LYMPHOCYTE COUNT; MALE; MICROSCOPY; MONOCLONAL IMMUNOGLOBULINEMIA; ORGAN DONOR; PERITONEAL DIALYSIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEINURIA; PYELONEPHRITIS; RECIPIENT; RECURRENT DISEASE; RETINA MACULOPATHY; STRESS FRACTURE; VISUAL IMPAIRMENT;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY TRANSPLANTATION; MIDDLE AGED; PARAPROTEINEMIAS; RECURRENCE;

EID: 33847175589     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2006.00437.x     Document Type: Article

References (13)

1. Daicker BC, Mihatsch MJ, Strom EH, Fogazzi GB. Ocular pathology in light chain deposition disease. Eur J Ophtalmol 1995; 5: 75.
2. Pozzi C, Fogazzi GB, Banfi G, Strom EH, Ponticelli C, Locatelli F. Renal disease and patient survival in light chain deposition disease. Clin Nephrol 1995; 43: 281.
3. Pozzi C, Locatelli F. Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol 2002; 22: 319.
4. Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12: 1482.
5. Pozzi C, D'Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003; 42: 1154.
6. Leung N, Lager DJ, Gertz MA, Wilson K, Kanakiriya S, Fervenza FC. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004; 43: 147.
7. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and non-malignant plasma cell disorders. Semin Oncol 2000; 27(6 Suppl. 12): 79.
8. Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003; 14: 1851.
9. Treon SP, Shima Y, Raje N, et al. Interferon-g induces CD20 expression on multiple myeloma cells via induction of Pu.1 and augments rituximab binding to myeloma cells. Blood 2000; 94(Suppl. 1): 119a.
10. Treon SP, Pilarski LM, Belch AR, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002; 25: 72.
11. Gemmel C, Cremer FW, Weis M, et al. Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Ann Hematol 2002; 81: 119.
12. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542.
13. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanisms of action. Am J Transplant 2006; 6: 859.